Clinical Trial Detail

NCT ID NCT01526928
Title Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Clovis Oncology, Inc.
Indications

lung non-small cell carcinoma

Therapies

Rociletinib

Age Groups: senior adult

Additional content available in CKB BOOST